NASDAQ
10.06.26 | 21:59
12,030 US-Dollar
-0,17 % -0,020
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | William Blair reiterates Cullinan Oncology stock rating on trial data | 3 | Investing.com | ||
| Mi | William Blair bestätigt "Outperform"-Rating für Cullinan Oncology nach Studiendaten | 1 | Investing.com Deutsch | ||
| CULLINAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mi | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases | 10 | GlobeNewswire (USA) | ||
| Mo | Cullinan Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Sa | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress | 3 | GlobeNewswire (USA) | ||
| 28.05. | Morocco and Finland Launch Business Council in Helsinki as Tazi Makes First European Outing as CGEM President | 2 | North Africa Post | ||
| 19.05. | Stifel reiterates Cullinan Oncology stock rating on trial data | 6 | Investing.com | ||
| 19.05. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia | 228 | GlobeNewswire (Europe) | Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Cullinan... ► Artikel lesen | |
| 18.05. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.05. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress | 1 | GlobeNewswire (USA) | ||
| 15.05. | Tazi and Bachiri Elected to Lead CGEM with 91.5% of the Vote | 1 | North Africa Post | ||
| 07.05. | CGEM Forum Reveals Only 6,000 Moroccan Firms Export, a Path to Change chartered | 2 | North Africa Post | ||
| 07.05. | Cullinan Therapeutics GAAP EPS of -$0.75 | 2 | Seeking Alpha | ||
| 07.05. | Cullinan Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.05. | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.03. | Gilead-Deal untermauert Potenzial: Clear Street bestätigt Kaufempfehlung für Cullinan Oncology | 18 | Investing.com Deutsch | ||
| 24.03. | Clear Street reiterates Cullinan Oncology stock rating on Gilead deal validation | 7 | Investing.com | ||
| 10.03. | Cullinan Therapeutics: Q4 Earnings Insights | 3 | Benzinga.com | ||
| 10.03. | Stifel raises Cullinan Oncology stock price target on autoimmune progress | 2 | Investing.com | ||
| 10.03. | Cullinan Therapeutics GAAP EPS of -$0.77 misses by $0.05 | 1 | Seeking Alpha |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| REGENXBIO | 5,306 | -0,04 % | H.C. Wainwright lowers Regenxbio stock price target on trial data | ||
| DBV TECHNOLOGIES | 2,776 | +2,06 % | DBV Technologies S.A.: DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference | Châtillon, France, June 9, 2026
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 5,640 | 0,00 % | Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher | ||
| CABALETTA BIO | 3,030 | -0,33 % | Cabaletta Bio, Inc. - 8-K, Current Report | ||
| TAYSHA GENE THERAPIES | 5,400 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| PRAXIS PRECISION MEDICINES | 240,66 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| PARABILIS MEDICINES | 31,850 | +0,79 % | HBM Healthcare Investments AG: HBM Healthcare Investments profitiert vom erfolgreichen Börsengang von Parabilis Medicines | HBM Healthcare Investments AG
/ Schlagwort(e): Börsengang
HBM Healthcare Investments profitiert vom erfolgreichen Börsengang von Parabilis Medicines
11.06.2026 / 07:00... ► Artikel lesen | |
| TANGO THERAPEUTICS | 28,690 | +0,03 % | Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 32,920 | 0,00 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| ERASCA | 13,370 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 82,72 | 0,00 % | RBC Capital raises Apogee Therapeutics stock price target to $97 | ||
| ADMA BIOLOGICS | 8,480 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen | |
| CG ONCOLOGY | 54,92 | 0,00 % | CG Oncology, Inc. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 13,030 | -0,15 % | Summit Therapeutics withdraws proposed securities offering citing market conditions | ||
| RELAY THERAPEUTICS | 13,490 | 0,00 % | Relay Therapeutics, Inc. - 8-K, Current Report |
CULLINAN THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 12,030 Euro und damit -0,17 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CULLINAN THERAPEUTICS INC finden Sie auf Wallstreet Online.